Drug repurposing for neglected and zoonotic diseases

Alexios-Fotios A Mentis; Helen W Hernandez; Kenneth I Kaitin

doi:10.1016/j.tips.2024.10.012

Drug repurposing for neglected and zoonotic diseases

Trends Pharmacol Sci. 2024 Dec;45(12):1100-1103. doi: 10.1016/j.tips.2024.10.012. Epub 2024 Nov 13.

Authors

Alexios-Fotios A Mentis¹, Helen W Hernandez², Kenneth I Kaitin³

Affiliations

¹ BGI-Shenzhen, Shenzhen, 518083, Guangdong, China; University of Athens Medical School, Athens, Greece. Electronic address: [email protected].
² KAL Research Initiatives LLC, Houston, TX 77042, USA.
³ Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, MA, USA.

PMID: 39542782
DOI: 10.1016/j.tips.2024.10.012

Abstract

Globalization and climate change have intensified the need to address the marginalization of R&D for neglected and zoonotic diseases. We propose that drug repurposing, using enabling technologies such as artificial intelligence, can address this need at a lower cost than de novo R&D processes.

Keywords: drug discovery; drug repurposing; epidemiology; neglected diseases; pharmaceuticals; pharmacology; zoonotic diseases.

MeSH terms

Animals
Artificial Intelligence
Drug Repositioning* / methods
Humans
Neglected Diseases* / drug therapy
Zoonoses* / drug therapy